Core Viewpoint - Awei Technology plans to invest 10 million yuan in Hunan Luying Technology Co., Ltd., marking its entry into the high-end nuclear medicine imaging equipment sector [1][2]. Investment Details - Awei Technology will invest 10 million yuan, participating in a total capital increase of 30 million yuan alongside other investors [1]. - After the investment, Awei Technology will hold a 9.07% stake in Luying Technology [1]. - The investment decision was made within the general manager's approval authority, requiring no board or shareholder meeting approval [1]. Company Background - Luying Technology, established on April 29, 2025, focuses on the development of domestic high-resolution single-photon emission computed tomography (SPECT) and its core components [1][3]. - The company aims to provide precise, safe, economical, and convenient molecular imaging diagnostic solutions [3]. Market Context - The global medical imaging and radiotherapy equipment market is experiencing rapid and stable growth [2]. - Government policies are promoting the domestic production of nuclear medicine imaging equipment, supporting the industry's development [2]. Product and Technology Insights - SPECT/CT is recognized for its clinical value in early diagnosis and evaluation of tumors, as well as its importance in cardiovascular, bone, and neurological imaging [2]. - Luying Technology's project team has experience in obtaining regulatory approval for SPECT/CT devices and holds core intellectual property, positioning it at an advanced level domestically [3]. Management and Ownership - The controlling shareholders of Luying Technology include key figures from Hunan University, indicating a strong academic and technical foundation [3]. - The company currently has no sales revenue and is still in the product development phase, which presents uncertainties regarding future profitability [3].

Core Insights - Awei Technology (688067) announced an investment of 10 million yuan in Hunan Luying Technology Co., Ltd., acquiring a 9.0744% stake in the company [2] Group 1: Investment Details - The investment is aimed at enhancing the synergy of Awei Technology's main business and improving its overall competitiveness [2] - The core business of Luying Technology involves the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components [2] Group 2: Strategic Significance - Awei Technology believes that this investment aligns with its long-term development plan and has positive strategic implications for its operations [2]

证券代码：688067 证券简称：爱威科技 公告编号：2025-042 爱威科技股份有限公司关于与专业投资机构 共同投资湖南麓影科技有限公司的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 投资标的名称： 湖南麓影科技有限公司（以下简称"麓影科技"或"标 的公司"） 投资金额：爱威科技股份有限公司（以下简称"公司"）以自有资金出 资人民币 1,000 万元对麓影科技进行增资。增资完成后，公司将持有麓影科技 9.0744%的股权。 （一）本次交易概况 1、本次交易概况 基于整体战略发展规划和实际经营需求，公司拟与国有专业投资机构广州广 金生命健康产业投资基金合伙企业（有限合伙）、湖南湘江新区引导一号创业投 资合伙企业（有限合伙）共同出资人民币 3,000 万元，认购麓影科技人民币 748.1296 万元新增注册资本。其中公司以自有资金出资人民币 1,000 万元，认 购麓影科技新增注册资本 249.3766 万元出资。本次增资完成后，公司将持有麓 影科技 9.0744%的股权。截至本公告披露日，公 ...

Core Viewpoint - Awei Technology (688067.SH) plans to invest a total of RMB 30 million in Luying Technology, acquiring a 9.0744% stake through a capital increase [1] Group 1: Investment Details - The investment will be made in partnership with state-owned investment institutions, including Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] - Awei Technology will contribute RMB 10 million, which will allow it to subscribe to RMB 249.3766 million of the new registered capital of Luying Technology [1] - The capital increase agreement has been signed among the investment parties and existing shareholders of Luying Technology [1] Group 2: Company Profile - Luying Technology, registered in Changsha, Hunan Province, has a registered capital of RMB 20 million [1] - The company specializes in the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components [1] - Luying Technology provides hospitals with precise, safe, economical, and convenient molecular imaging diagnostic solutions, focusing on high-end nuclear medicine imaging and treatment equipment [1]

Core Viewpoint - Awei Technology (688067.SH) plans to invest a total of RMB 30 million in Luying Technology, acquiring a 9.0744% stake through a capital increase [1] Group 1: Investment Details - The investment will be made in partnership with state-owned investment institutions, including Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] - Awei Technology will contribute RMB 10 million, which will allow it to subscribe for RMB 2.493766 million of the new registered capital of Luying Technology [1] - The capital increase agreement has been signed among the investment parties and existing shareholders of Luying Technology [1] Group 2: Company Profile - Luying Technology, registered in Changsha, Hunan Province, has a registered capital of RMB 20 million [1] - The company specializes in the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components [1] - Luying Technology provides hospitals with precise, safe, economical, and convenient molecular imaging diagnostic solutions, focusing on high-end nuclear medicine imaging and treatment equipment [1]

Core Viewpoint - Aiwai Technology (688067.SH) announced a joint investment of 30 million yuan in Luying Technology, indicating a strategic move to expand its portfolio in the medical imaging sector [1] Group 1: Investment Details - The company will contribute 10 million yuan to the investment, resulting in a 9.0744% equity stake in Luying Technology after the capital increase [1] - The investment is made in collaboration with Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] Group 2: Company and Product Status - Luying Technology is a relatively new company that currently has no sales revenue and has not yet achieved profitability [1] - The core product, high-end medical imaging SPECT/CT, is still under development, with uncertainties regarding successful research and the completion of medical device certification [1]

Core Viewpoint - Aivi Technology (688067) plans to invest 30 million yuan in Hunan Luying Technology Co., Ltd. by subscribing to its newly registered capital of 7.4813 million yuan, acquiring a 9.07% stake post-investment [1] Group 1 - Aivi Technology will contribute 10 million yuan to the investment [1] - The investment is made in collaboration with state-owned investment institutions, Guangzhou Guangjin Life Health Industry Investment Fund and Hunan Xiangjiang New Area Guidance No. 1 Venture Capital Partnership [1] - The total investment amount for the project is 30 million yuan [1]

爱威科技(688067.SH)公告，公司以自有资金出资1000万元对麓影科技进行增资。增资完成后，公司将 持有麓影科技9.0744%的股权。据公告信息所示，麓影科技主营业务为国产化高分辨率单光子发射计算 机断层扫描仪(SPECT)及其核心元器件的开发，为医院提供精准、安全、经济、便捷的分子影像诊断技 术方案。核心产品是国产化SPECT和SPECT/CT及其核心元器件，属于高端核医学影像诊疗设备。 ...

Core Viewpoint - The company Awei Technology (688067.SH) has announced an investment of 10 million yuan in Luying Technology, acquiring a 9.0744% stake in the latter [1] Company Summary - Awei Technology is investing its own funds to enhance its stake in Luying Technology, indicating a strategic move to strengthen its position in the high-end medical imaging sector [1] - Luying Technology specializes in the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components, providing advanced molecular imaging diagnostic solutions for hospitals [1] Industry Summary - The core products of Luying Technology include domestically produced SPECT and SPECT/CT systems, which are categorized as high-end nuclear medicine imaging and diagnostic equipment [1]

Core Insights - Awei Technology's stock decreased by 1.51% on October 9, with a trading volume of 37.03 million yuan [1] - The company reported a financing buy-in of 4.30 million yuan and a net financing buy of 0.96 million yuan on the same day [1][2] - As of October 9, the total financing and securities lending balance for Awei Technology was 47.96 million yuan, accounting for 2.76% of its market capitalization [1] Financing Overview - On October 9, Awei Technology had a financing buy-in of 4.30 million yuan, with a financing balance of 47.96 million yuan, which is above the 80th percentile of the past year [1] - The company had no securities lending activity on October 9, with a securities lending balance of 0.00 yuan, indicating a high level of inactivity in this area [1] Business Performance - As of June 30, Awei Technology had 4,086 shareholders, an increase of 13.34% from the previous period, while the average circulating shares per person decreased by 11.77% [2] - For the first half of 2025, Awei Technology achieved a revenue of 110 million yuan, representing a year-on-year growth of 12.70%, and a net profit of 14.06 million yuan, up 21.16% year-on-year [2] Dividend Information - Since its A-share listing, Awei Technology has distributed a total of 40.73 million yuan in dividends, with 20.33 million yuan distributed over the past three years [3] - As of June 30, 2025, the ninth largest circulating shareholder is Nuoan Multi-Strategy Mixed A, holding 477,400 shares as a new shareholder, while Anxin Medical Health Stock A has exited the top ten circulating shareholders [3]